Oncorus. has filed a patent for oncolytic viral vectors that can be used for the treatment and prevention of cancer. The vectors incorporate features such as viral replication restriction, disruption of oncogenic microRNA function, cancer microenvironment remodeling, and cancer cell targeting. The patent claims a recombinant oncolytic herpes simplex virus (HSV) with micro-RNA target sequences inserted into essential viral genes, resulting in reduced replication in non-cancerous cells compared to cancerous cells of the same type. GlobalData’s report on Oncorus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Oncorus, Oncolytic viruses was a key innovation area identified from patents. Oncorus's grant share as of September 2023 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
Recombinant oncolytic herpes simplex virus for cancer treatment
A recently filed patent (Publication Number: US20230241140A1) describes a recombinant oncolytic herpes simplex virus (HSV) that has been engineered to target cancer cells while sparing non-cancerous cells. The virus contains micro-RNA (miRNA) target sequences inserted into essential viral genes, which reduces its replication in non-cancerous cells compared to cancerous cells of the same type. The viral genes targeted include ICP4, ICP27, ICP8, ICP22, ICP34.5, UL5, UL8, UL9, UL30, UL39/40, and UL42.
The patent claims also specify different combinations of viral genes and miRNA target sequences for specific cell types. For example, in brain cells, the miRNA target sequences include miR-137, miR-219a, miR-124, miR-9, miR-487b, and miR-128. In cardiac or striated muscle cells, the miRNA target sequences include miR-208b, miR-1, miR-208a, miR-133a, miR-4284, miR-499a, miR-126, miR-30e, miR-378i, miR-30b, and miR-378. Similar combinations are specified for spinal cord cells, peripheral nervous system cells, liver cells, and smooth muscle cells.
The patent also describes the incorporation of miRNA target sequences into a miR-T cassette, which is inserted into the untranslated regions (UTR) of the viral genes. The length of the miR-T cassette can range from less than 1000 nucleotides to between 25 and 500 nucleotides.
Furthermore, the patent claims the inclusion of heterologous polynucleotide sequences encoding payload molecules in the recombinant HSV. These payload molecules can include IL-12, CCL4, CXCL10, or combinations thereof. The patent also mentions the use of protease-activated antibodies and other proteins or oligonucleotides to reduce the expression or inhibit the function of miRNAs, genes, or tissue inhibitors of metalloproteinases (TIMPs).
The patent covers various methods of using the recombinant oncolytic virus, including killing cancerous cells by exposing them to the virus, treating cancer in subjects by administering the virus, and delivering payload molecules or proteins to cancer cells using the virus. The patent also mentions specific cancer types that can be targeted, such as lung cancer, breast cancer, ovarian cancer, prostate cancer, and melanoma.
Overall, this patent describes a novel recombinant oncolytic HSV that has been engineered to selectively target and kill cancer cells while minimizing harm to non-cancerous cells. The inclusion of miRNA target sequences and payload molecules enhances the specificity and effectiveness of the virus in treating various types of cancer.
To know more about GlobalData’s detailed insights on Oncorus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
